Milestone Pharmaceuticals Inc.
etripamil
paroxysmal supraventricular tachycardia (PSVT)
Resolved
102days ago
Approval decision · Mar 27, 2026
What's at stake
A final FDA approval decision on etripamil for paroxysmal supraventricular tachycardia (PSVT) is expected Mar 27, 2026.
Primary source
· SEC 8-K
verified 15h ago
“Express Scripts added CARDAMYST nasal spray to its commercial national formularies, effective March 27, 2026.”